Chemotherapy-induced peripheral neuropathy common in early stage breast cancer
the ONA take:
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer and was strongly associated with docetaxel-based regimens, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
For the study, researchers from the Portuguese Institute of Oncology of Porto in Portugal sought to estimate the incidence of CIPN, identify factors associated with occurrence, and determine its impact on patient-reported outcomes.
Researchers enrolled 296 patients with incident breast cancer planning to receive chemotherapy. Patients were followed for 1 year.
Results showed that the cumulative incidence of CIPN in the first year after cancer diagnosis was 28.7% and more than 80% of participants were symptomatic 6 months after diagnosis.
The researchers found that patients who received docetaxel-based regimens were at a higher risk for developing CIPN, while alcohol consumption and diabetes were not significantly associated with CIPN.
“Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes,” the authors conclude.
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|